Corbus Pharmaceuticals (CRBP) & Its Rivals Head to Head Survey

Corbus Pharmaceuticals (NASDAQ: CRBP) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Corbus Pharmaceuticals to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Valuation and Earnings

This table compares Corbus Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corbus Pharmaceuticals $1.91 million -$19.99 million -11.19
Corbus Pharmaceuticals Competitors $284.28 million $33.78 million 84.49

Corbus Pharmaceuticals’ peers have higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Corbus Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals -1,040.41% -96.02% -77.38%
Corbus Pharmaceuticals Competitors -5,311.45% -218.34% -39.53%

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals’ peers have a beta of 6.03, indicating that their average share price is 503% more volatile than the S&P 500.

Insider & Institutional Ownership

27.8% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 11.9% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Corbus Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals 0 0 3 0 3.00
Corbus Pharmaceuticals Competitors 860 3211 11652 231 2.71

Corbus Pharmaceuticals currently has a consensus price target of $23.67, indicating a potential upside of 235.70%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.37%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than its peers.

Summary

Corbus Pharmaceuticals peers beat Corbus Pharmaceuticals on 7 of the 12 factors compared.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply